The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Eralp, Y.Ak, N.Yilmazbayhan, D.Ozkan, B.Ferhatoglu, F.Demirkazik, A.Sak, S. DizbayDilege, S.Tanju, S.Toker, A.Bulutay, P.Firat, P.Mandel, N. MolinasKilickap, S.Onder, S.Dikmen, E.Alan, O.Yumuk, P. F.Bozkurtlar, E.Lacin, T.Ozturk, A.Kocaturk, C.Karapinar, K.Urer, N.Uluc, B. Oyan2023-02-212023-02-212019-01-0110.1016/j.jtho.2019.08.1934https://hdl.handle.net/11443/2605http://dx.doi.org/10.1016/j.jtho.2019.08.1934The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group StudyArticleWOS:000492162204418